Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 50

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 3
Chunk 50
---
�───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  the occurrence of economic weakness, including inflation or political instability;                                                                                                                    
  the effects of applicable non-U. S. tax structures and potentially adverse tax consequences;                                                                                                          
  differences in protection of our IP rights including patent rights of other parties;                                                                                                                  
  the burden of complying with a variety of foreign laws including difficulties in effective enforcement of contractual provisions;                                                                     
  delays resulting from difficulty in obtaining export licenses, tariffs and other barriers and restrictions, potentially longer payment cycles, greater difficulty in accounts receivable collecti...  
  production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad.                                                                                    

In addition, we are subject
to general geopolitical risks in foreign countries where we operate, such as political and economic instability and changes in diplomatic
and trade relationships, which could affect, among other things, customers’ inventory levels and consumer purchasing, which could
cause our results to fluctuate and our net sales to decline. The occurrence of any one or more of these risks of doing business internationally,
individually or in the aggregate, could materially and adversely affect our business and results of operations.

If we engage in future acquisitions or strategic
partnerships, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities,
and subject us to other risks.

We may evaluate various acquisitions
and strategic partnerships, including licensing or acquiring complementary products, IP rights, technology or businesses. Any potential
acquisition or strategic partnership may entail numerous risks, including, but not limited to:

  increase in operating expenses and cash requirements;  
 ─────────────────────────────────────────────────────────

  the assumption of additional indebtedness or contingent liabilities;  

  the issuance of our equity securities;  

  assimilation of operations, IP and products of an acquired company, including difficulties associated with integrating new personnel;  

  the diversion of our management’s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;  

  retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;  

  risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing drugs or drug and diagnostics technology candidates and r...  

  our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even